Ongoing study Official Study Title CLARITHROMYCIN TO PREVENT SECONDARY INFECTIONS IN PATIENTS WITH SEPSIS FOLLOWING LOWER RESPIRATORY TRACT INFECTIONS Brief Description The goal of this clinical trial is to assess whether clarithromycin, given as an adjunct to standard-of-care antibiotic therapy, can reduce the risk of new infections and secondary sepsis in adult patients hospitalized
Vasiliki Bourika, Evangelia-Areti Rekoumi and Evangelos J. Giamarellos-Bourboulis Ann Intensive Care. 2025 Jul 21;15(1):103 DOI: 10.1186/s13613-025-01524-1Download pdf 🡇 Funding No funding was provided for this manuscript. Keywords: Sepsis, Biomarkers, Guidance, Antibiotics, Fluids, Vasopressors
Evdoxia Kyriazopoulou, Antigone Kotsaki, Asimina Safarika, Garyfallia Poulakou, Haralampos Milionis, Simeon Metallidis, Georgios Adamis, Archontoula Fragkou, Aggeliki Rapti, Pierluigi Del Vecchio, Ioannis Kalomenidis, Danae Kitzoglou, Andrea Angheben, Ilias Kainis, Konstantina Iliopoulou, Francesco Saverio Serino, Petros Bakakos, Vassiliki Tzavara, Sofa Ioannou, Lorenzo Dagna, Katerina Dimakou, Glykeria Tzatzagou, Maria Chini, Matteo Bassett, Vasileios Kotsis, George Tsoukalas,
Evdoxia Kyriazopoulou, Emmanouil Stylianakis, Georgia Damoraki, Panagiotis Koufargyris, Ioannis Kollias, Konstantina Katrini, Elina Drakou, Konstantinos Marousis, Andronikos Spyrou, Styliani Symbardi, Nikolaos Alexiou, Zoi Alexiou, Malvina Lada, Garyfallia Poulakou, Georgios Chrysos, George Adamis, Evangelos J. Giamarellos-Bourboulis Int J Antimicrob Agents. 2025 Apr 9:107507 DOI: 10.1016/j.ijantimicag.2025.107507 View article 🡆 FundingHellenic Institute for the Study of Sepsis
Completed studyOfficial Study TitleEMapalumaB treatment foR Anticipated Clinical benefit in sepsis driven by the Interferon-Gamma Endotype (The EMBRACE trial)Brief DescriptionIn a recent analysis of 5,503 patients with sepsis meeting the Sepsis-3 definitions and coming from Germany, Greece and Italy randomized into one discovery set and one validation set, it was found that one endotype driven
Antonios Arapis, Dimitrios Panagiotopoulos, Evangelos J. Giamarellos-Bourboulis Burns & Trauma, 2025, 13, tkaf001 DOI: 10.1093/burnst/tkaf001Download pdf 🡇 Keywords: Precision immunotherapy; Sepsis; Anakinra; Nangibotide; Nivolumab; Interferon-gamma; Growth factors; Adrecizumab
Evangelos J. Giamarellos-Bourboulis, Massimo Antonelli, Frank Bloos, Ioanna Kotsamidi, Christos Psarrakis, Konstantina Dakou, Daniel Thomas-Rüddel, Luca Montini, Josef Briegel, Georgia Damoraki, Panagiotis Koufargyris, Souzana Anisoglou, Eleni Antoniadou, Glykeria Vlachogianni, Christos Tsiantas, Matteo Masullo, Aikaterini Ioakeimidou, Eumorfia Kondili, Maria Ntaganou, Eleni Gkeka, Vassileios Papaioannou, Effie Polyzogopoulou, Armin J Reininger, Gennaro De Pascale, Michael Kiehntopf, Eleni